经皮冠脉介入治疗病人围手术期应用β-受体阻滞剂的作用  

Application of β-adrenergic blocker during perioperational period to patients receiving PCI therapy

作　　者：辛辉[1] 蔡尚郎[1] 

机构地区：[1]青岛大学医学院附属医院心内科,266003

出　　处：《中国实用内科杂志》2005年第10期893-894,共2页Chinese Journal of Practical Internal Medicine

基　　金：山东省卫生厅青年基金资助(编号2001CA2CBB5)

摘　　要：目的评价经皮冠脉介入治疗(PCI)前应用β-受体阻滞剂对病人的保护作用.方法对青岛大学医学院附属医院 1997～2004年间行PCI治疗病人210例,随机分为β-受体阻滞剂组(105例)及对照组(105例).分别于术前、术后6～8 h及16～24 h抽取血标本检测心肌肌酸激酶(CK-MB)、肾上腺素(E)、去甲肾上腺素(NE)值,并随访病人院内、院外1年心脏事件的发生率.结果 (1)两组间CK-MB、E、NE值均无统计学意义.同组间,不同时间内CK-MB、E、NE值差异亦无显著性.(2)服β-受体阻滞剂组院内病死率较未服者低(2.1% 比4.1%),1年随访β-受体阻滞剂组院内病死率亦较未服者低(5.5% 比7.1%).结论 PCI治疗前应用β-受体阻滞剂对病人有保护作用.Objective To evaluate the protective effect of prior β-adrenergic blocker therapy to patients who have PCI therapy. Methods We analyzed 210 consecutive patients undergoing β-adrenergic blocker, of whom 105 did β-adrenergic blocker therapy, 105 had not. CK - MB, E, NE were tested before PCI, and 6 ～ 8 h, 16 ～ 24 h after PCI, Procedural complications in hospital and 1-ear outside outcomes were evaluated, Results （ 1 ） There was no significant difference between the two groups on CK - MB, E, NE. （2） Both the in-hospital （2. 1% vs 4. 1% ） and one year （5, 5% vs 7. 1% ） mortality was lower in β-group than in no ～ 13 group, Conclusion Prior β-adrenergic blocker therapy can reduce the incidence of cardic events.

关 键 词：经皮冠脉介入治疗 Β-受体阻滞剂 

分 类 号：R5[医药卫生—内科学]